KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2025)

Historic Short term Debt for Rigel Pharmaceuticals (RIGL) over the last 3 years, with Q3 2025 value amounting to $29.8 million.

  • Rigel Pharmaceuticals' Short term Debt changed N/A to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year change of. This contributed to the annual value of $7.3 million for FY2024, which is 59.48% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Short term Debt stood at $29.8 million.
  • Over the past 5 years, Rigel Pharmaceuticals' Short term Debt peaked at $29.8 million during Q3 2025, and registered a low of $7.2 million during Q4 2023.
  • Moreover, its 3-year median value for Short term Debt was $14.8 million (2024), whereas its average is $16.0 million.
  • In the last 5 years, Rigel Pharmaceuticals' Short term Debt surged by 59.48% in 2024 and then grew by 23.68% in 2025.
  • Rigel Pharmaceuticals' Short term Debt (Quarter) stood at $7.2 million in 2023, then grew by 0.59% to $7.3 million in 2024, then surged by 309.25% to $29.8 million in 2025.
  • Its Short term Debt was $29.8 million in Q3 2025, compared to $22.4 million in Q2 2025 and $14.8 million in Q1 2025.